PFKM and cancer: By taking into account these considerations, we propose that administration of citrate at high doses could reinforce the efficacy of PI3K and YAP/TAZ inhibitors currently used against cancer cells since (by inhibiting PFK1) it can contribute to disrupt the positive feedback loop between these two signaling pathways and PFK1/F-1,6-BP.